Exelixis, Inc. (EXEL)
| Previous Close | 23.29 |
| Open | 23.20 |
| Bid | 23.69 x 100 |
| Ask | 23.74 x 100 |
| Day's Range | 23.19 - 23.74 |
| 52 Week Range | 18.08 - 24.34 |
| Volume | |
| Avg. Volume | 2,259,487 |
| Market Cap | 6.996B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | 36.51 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
ALAMEDA, Calif., April 16, 2024--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
- Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
ALAMEDA, Calif., February 27, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March:
- Business Wire
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
ALAMEDA, Calif., February 06, 2024--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
